Long-term follow-up after KYV-101 (CAR T) treatment
Official title: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Run by Kyverna Therapeutics · NCT07403188 · Data updated 2026-11-12
This follow-up will test how long KYV-101 CAR T cells persist and record any delayed side effects in people who previously received KYV-101 for autoimmune diseases like lupus nephritis, myasthenia gravis, stiff person syndrome, rheumatoid arthritis, or multiple sclerosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Kyverna Therapeutics Industry-sponsored |
| Drugs / interventions | CAR T |
| Locations | 1 site (Denver, Colorado) |
| Status | Recruiting |
| Started | November 24, 2025 |
| Main results expected | January 2041 |
| Study ends | January 2041 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT07403188 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people who previously received at least one infusion of KYV-101 in a prior Kyverna-sponsored or investigator-initiated trial and can provide informed consent for follow-up visits and testing.
✕Probably not a fit
People who have never received KYV-101 or who need active therapeutic intervention rather than monitoring are unlikely to receive direct clinical benefit from this follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational long-term follow-up open to anyone who received at least one infusion of the autologous gene-modified cell therapy KYV-101 in a prior Kyverna-sponsored or investigator-initiated protocol. Participants will have periodic safety checks and laboratory testing to capture delayed adverse events and to measure persistence of the KYV-101 product in blood or other samples. The protocol is non-interventional and focuses on monitoring rather than providing new therapy. Collected data will inform the long-term safety profile and durability of the engineered CAR T cells across multiple autoimmune indications.
Why it matters
Potential benefit: If successful, the study could clarify long-term safety and how long KYV-101 cells remain detectable, helping guide future monitoring and care for treated patients.
How similar studies have gone: Long-term follow-ups of CAR T therapies in oncology have shown durable cell persistence and occasional delayed toxicities, but long-term data for CAR T approaches in autoimmune diseases like KYV-101 remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provided informed consent for the LTFU study * Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol Exclusion Criteria: * Not applicable
Where it's running
-
University of Colorado, Denver
Denver, Colorado, United States Recruiting
Study contacts
- Study coordinator: Kyverna Therapeutics
- Email: clinicaltrials@kyvernatx.com
- Phone: 510-925-2484
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
Using long-lived immune cells to calm an overactive immune system
This trial will try QEL-005, an autologous CD19-directed CAR-T regulatory cell therapy, to calm immune overactivity in adults with diffuse cutaneous systemic sclerosis or difficult-to-treat rheumatoid arthritis.
-
Personalized lab test to predict the best treatment for rheumatic diseases
This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.
-
Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases
This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.
-
HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases
This will test a single infusion of HBI0101 CAR‑T cells in adults with severe, treatment‑resistant B‑cell autoimmune diseases such as SLE, systemic sclerosis, idiopathic inflammatory myopathy, rheumatoid arthritis, or primary progressive MS.
-
AlloNK® therapy combined with rituximab for treating certain autoimmune diseases
This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.